KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Rigel Pharmaceuticals (RIGL) Long-Term Debt Repayments (2010 - 2026)

Rigel Pharmaceuticals' quarterly Long-Term Debt Repayments came in at $7.5 million in Q1 2026, up 5497.01% quarter-over-quarter from $134000.0 in Q4 2011.

Rigel Pharmaceuticals has reported Long-Term Debt Repayments for 3 years, with the latest figure at $7.5 million in Q1 2026.

  • For the quarter ending Q1 2026, Long-Term Debt Repayments changed N/A year-over-year to $7.5 million; the trailing twelve-month figure through Mar 2026 stood at $7.6 million (up 2323.49% YoY), and the FY2025 full-year result was $7.5 million, changed N/A from the prior year.
  • Long-Term Debt Repayments for Q1 2026 stood at $7.5 million, up from $134000.0 in the prior quarter.
  • The five-year high for Long-Term Debt Repayments was $7.5 million in Q1 2026, with the low at $7.5 million in Q1 2026.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn -
10 Rigel Pharmaceuticals 551.62 Mn 404.94 Mn 54.21 Mn 7.50 Mn

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 7.50 Mn
Mar 31, 2026 7.50 Mn
Dec 31, 2011 134,000.00
Dec 31, 2011 134,000.00
Sep 30, 2011 181,000.00
Sep 30, 2011 181,000.00
Jun 30, 2011 234,000.00
Jun 30, 2011 234,000.00
Mar 31, 2011 251,000.00
Mar 31, 2011 251,000.00
Dec 31, 2010 265,000.00
Dec 31, 2010 265,000.00
Sep 30, 2010 269,000.00
Sep 30, 2010 269,000.00